Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

NACDS seeks amendments to Reye's syndrome bill

  • News

Executive Summary

Natl. Assn. of Chain Drug Stores in comments to House Commerce/Health Subcmte. Chairman Waxman (D-Calif.) said bill to require retailers to provide within 30 days of enactment warning notices, advertising, and new labeling regarding the association between aspirin and Reye's syndrome would pose logistical compliance problems. Assn. urged "a more reasonable timetable" of 60 days for retail warning notices, 90 days to bring ads into compliance, and 270 days to relabel.

Table

View full table

Tags:
Latest Headlines

Brand Drug Shortages Complicate US FDA Messaging To Congress

Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks, Platform Principles Without Designation

FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why

See All
UsernamePublicRestriction

Register

PS008173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By